2-Hydroxyoleic acid - Lipopharma Therapeutics

Drug Profile

2-Hydroxyoleic acid - Lipopharma Therapeutics

Alternative Names: 2-hydroxy-9-cis octadecenoic - Lipopharma; 2-OHOA - Lipopharma Therapeutics; LP561A1; Minerval

Latest Information Update: 23 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of the Balearic Islands
  • Developer Lipopharma
  • Class Anorectics; Antineoplastics; Oleic acids
  • Mechanism of Action Membrane lipid modulators; Phosphatidylcholine ceramide phosphocholine transferase stimulants; Ras signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glioma; Solid tumours

Most Recent Events

  • 21 Jan 2018 Lipopharma receives grant from European Commission for 2-hydroxyoleic acid development in glioma
  • 21 Jan 2018 Lipopharma plans to apply for a conditional approval of 2-hydroxyoleic acid in Europe for the treatment of Glioblastoma (Newly diagnosed, Combination therapy)
  • 21 Jan 2018 Lipopharma plans a phase IIb trial for Glioblastoma (Newly diagnosed, Combination therapy) in Europe and Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top